Back
Cadrenal Therapeutics, Inc. Stock Predictions
14K Investors Got In Earlier. You Still Can.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
42
CVKD
Cadrenal Therapeutics, Inc.
Last Price:
$10.99
Seasonality Move:
35.81%
7 Day Trial
ALL ACCESS PASS
$
7
Valuation Up 5,000%. Shares Now $0.85 - Still Early?
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiCadrenal Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Cadrenal Therapeutics, Inc. has on average historically risen by 23.6% based on the past 2 years of stock performance.
-
Cadrenal Therapeutics, Inc. has risen higher in 1 of those 2 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
-
Is Cadrenal Therapeutics, Inc. Stock Undervalued?The current Cadrenal Therapeutics, Inc. [CVKD] share price is $11.00. The Score for CVKD is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.
-
CVKD is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
Will Cadrenal Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Cadrenal Therapeutics, Inc. has on average historically risen by 23.6% based on the past 2 years of stock performance.
Cadrenal Therapeutics, Inc. Stock Rating
Sell
42
Cadrenal Therapeutics, Inc. (CVKD)
is a Sell
Is Cadrenal Therapeutics, Inc. overpriced?
-
Cadrenal Therapeutics, Inc. has risen higher in 1 of those 2 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Cadrenal Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
cadrenal.com
52-Week Data
52-Week High:
22.90
52-Week Low:
8.12
Prediction Charts
Market Cap:
22.8M
Price in USD:
11.00
Volume:
105.1K
Beta:
1.05
Technical Analysis
SMA50:
12.05
SMA100:
12.29
SMA200:
13.72
52-Wk Change:
-5.17%
Stock Predictions
-
Is Cadrenal Therapeutics, Inc. stock public?Yes, Cadrenal Therapeutics, Inc. is a publicly traded company.
-
What is the Cadrenal Therapeutics, Inc. stock quote today?The Cadrenal Therapeutics, Inc. stock price is 11.00 USD today.
-
How to buy Cadrenal Therapeutics, Inc. stock online?You can buy Cadrenal Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-24 | 10.26 | 10.04 | 11.29 | 10.04 |
| Nov-25 | 10.09 | 9.92 | 10.28 | 9.38 |
| Nov-26 | 9.90 | 9.38 | 10.07 | 9.30 |
| Nov-28 | 9.42 | 9.39 | 9.56 | 9.36 |
| Dec-1 | 9.05 | 9.00 | 9.27 | 8.66 |
| Dec-2 | 8.73 | 8.27 | 8.97 | 8.20 |
| Dec-3 | 8.26 | 8.86 | 8.86 | 8.12 |
| Dec-4 | 9.66 | 11.10 | 11.58 | 9.66 |
| Dec-5 | 11.04 | 10.18 | 11.04 | 9.84 |
| Dec-8 | 10.18 | 9.93 | 10.31 | 9.85 |
| Dec-9 | 9.85 | 9.97 | 10.21 | 9.55 |
| Dec-10 | 10.00 | 11.11 | 11.30 | 9.99 |
| Dec-11 | 11.96 | 11.00 | 12.00 | 10.60 |
| Dec-12 | 11.34 | 11.00 | 11.44 | 10.83 |
Cadrenal Therapeutics, Inc. Earnings
Cadrenal Therapeutics, Inc. Earnings Report: Per Share Cadrenal Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Cadrenal Therapeutics, Inc. Forecast Revenue Growth
Cadrenal Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Cadrenal Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $0.04 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.43 per share, and an increase next year of $1.39 per share.
* Cadrenal Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.